Amino acids are important nutrients for proliferating tumor cells, so their transport is generally increased in many malignant tumor cells. Radiolabeled amino acids are of great interest as they can be alternative or complement tracers to the already wellestablished radiopharmaceuticals such as 18 F-FDG. 
Introduction
Positron emission tomography (PET) has become an established method for medical research and clinical routine diagnostics because of its high sensitivity. The development and availability of new radiopharmaceuticals is one of the major conditions of the expansion of clinical PET. Nowadays a glucose analog, 2-18 F-fluoro-2-deoxy-D-glucose ( 18 F-FDG), is the most widely used as a PET tracer. Although 18 F-FDG has been successfully used in many cancers as a biomarker of glucose transport, it fails in diagnosis of Ga offers appropriate decay properties (T 1/2 = 67.7 min, β + = 89%, E = 1.9 MeV) and the long physical T 1/2 of the parent radionuclide (270.8 d) allows the use of the generator for up to one year [5] .
In this study, we evaluated the biodistribution of natural amino acid leucine labeled with 68 Ga in Wistar rats bearing cholangioma RS-1 tumor xenografts.
Materials and methods
Biodistribution studies were performed in Wistar rats weighing 140-160 g with tumor xenografts of cholangioma RS-1. To get a solid form of cholangioma RS-1 the donor rat with tumor was killed by cervical disruption, and the tumor tissue was isolated.
Then the tumor tissue was ground up, diluted in physiological saline and implanted subcutaneously in rats. Biodistribution studies were performed after 8-10 days, when the tumor volume reached 0.7-0.8 cm 3 .
32 Wistar rats with tumor xenografs were injected with 0.37 MBq of 68 Ga-leucine The results from the biodistribution data for each group of mice were expressed as mean value and standard error of the mean (M ± m). Student's t test was used to analyze data throughout all studies between groups at different time points, and p<0.05 was considered statistically significant.
Results and discussion
The results of biodistribution studies of 68 Ga-leucine are presented in Table 1 . It was revealed that tumor uptake of 68 Ga-leucine was 0.79% ID/g at 5 min, 0.36% ID/g at 1 h, 0.32% ID/g at 3 h, and 0.29% ID/g at 5 h. These values were 2-4 times higher as compared with 68 GaCl 3 .
Amino acids are transported into cells by specific carrier-mediated transport system.
Large neutral L-amino acids such as leucine are substrates of system L amino acid transporters. The level of one of these, LAT1, is overexpressed in many tumors [3] . For example, a new L-leucine analog, 5-[ 18 F]fluoroleucine is taken up by tumor cells via LAT1 transporter [6, 7] . One of the potential limitations of system L substrates is the ability of these transporters to mediate both influx and efflux of substrates, limiting the tumor-to-background ratios that can be achieved. It can explain a lack of radioactivity in tumor tissue after intravenous injection of 68 Ga-leucine.
The activity level in kidneys was the highest immediately after intravenous injection of 68 Ga-leucine (up to 4.60% ID/g). However, the uptake of radioactivity in kidneys was found to reduce with time, indicating that the excretion of injected activity was occurred through the urinary routes.
The radioactivity in the blood was as high as 1.40% ID/g at 5 min, but then it decreased to 0.58-0.63% ID/g and remained constant within 5 h. The levels of 68 GaCl 3 were higher as compared with 68 Ga-leucine due to remarkable protein binding capacity
It is known that free 68 Ga has high affinity to hydroxyapatite and cortical matrix of bone [8] . Femur uptake of 68 GaCl 3 reached 3.03% ID/g at 1 h after injection, whereas the highest activity of 68 Ga-leucine was 0.27% ID/g only. It is the evidence of high in vivo stability of 68 Ga-leucine.
The amounts of radioactivity in other organs such as lungs, liver, heart, spleen, stomach, small intestine, muscle and brain, didn't exceed 1% ID/g. Only uptake of 68 Galeucine in spleen reached 1.12% ID/g at 1 h. 
